NCT07014683

Brief Summary

The goal of this clinical trial is to learn if INCREM intervention can improve psychosocial functioning in patients with remitted major depressive disorder. The main question it aims to answer are: Does INCREM improve psychosocial functioning compared to psychoeducation? Does the benefits of INCREM remain after six months of the intervention compared to psychoeducation? Researchers will compare two arms: INCREM; psychoeducation to see if psychosocial functioning improves. Participants will be allocated to:

  • INCREM
  • Psychoeducation
  • TAU.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
101

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 19, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 13, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 13, 2023

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

May 30, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 11, 2025

Completed
Last Updated

June 11, 2025

Status Verified

September 1, 2024

Enrollment Period

1.9 years

First QC Date

May 30, 2025

Last Update Submit

May 30, 2025

Conditions

Keywords

cognitive symptomscognitive remediationrehabilitationfunctional recoverymajor depressive disorder

Outcome Measures

Primary Outcomes (1)

  • Functioning Assessment Short Test (FAST)

    The FAST is a valid, widely used instrument to test psychosocial functioning. The main outcome measure will be the percentage of change in FAST scores between T0 and T1 and T2.

    From enrollment to the end of treatment (12 weeks) and to the end of follow-up (6 months)

Secondary Outcomes (3)

  • Hamilton Depression Rating Scale-17 items (HDRS_17)

    From enrollment to the end of treatment (12 weeks) and to the end of follow-up (6 months)

  • Screening for Cognitive Impairment in Psychiatry (SCIP)

    From enrollment to the end of the intervention (12 weeks) and to the end of the follow-up (6 months)

  • Perceived Deficits Questionnaire for Depression (PDQ-R)

    From enrollment to the end of the intervention (12 weeks) and to the end of follow-up (6 months)

Study Arms (2)

INCREM

EXPERIMENTAL

12-session integral cognitive remediation program specifically designed for depression.

Behavioral: INCREM

Psychoeducation

ACTIVE COMPARATOR

12-session psychoeducation program for depression

Behavioral: Psychoeducation

Interventions

INCREMBEHAVIORAL

This is a specifically designed program to improve psychosocial functioning which targets cognitive symptoms.

Also known as: cognitive remediation
INCREM
PsychoeducationBEHAVIORAL

This is a 12-session psychoeducation program designed as an active comparator for the current trial

Psychoeducation

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients aged 18-60 y.o. and beyond with a remitted or active episode of major depression (DSM-5 criteria; maximum score of 18-20 on the HDRS-17) showing cognitive symptoms (scores below 80 on the SCIP) with functional difficulties (scores above 12 on the FAST).

You may not qualify if:

  • IQ below 85;
  • any unstable or inadequately-treated medical condition that may affect neuropsychological performance;
  • being under drug treatment in the last 4 weeks with glucocorticoids, probiotics, non-steroidal anti-inflammatory drugs, bile acid sequestrants, immunosuppressive drugs, anti-histamines, mast cell stabilizers, and antioxidant supplements;
  • use of systemic antibiotics the last 2 months;
  • presence of any comorbid psychiatric condition, other than personality disorders or nicotine use disorders, in the last three months;
  • accomplish criteria for severe treatment resistant depression;
  • patients who had received electroconvulsive therapy in the previous year;
  • patients receiving any other structured psychological intervention in the 3 months prior to the study;
  • not having the necessary electronic means (computer or tablet) or internet connection to be able to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut de Recerca Sant Pau- Mental Health Group

Barcelona, Catalonia, 08041, Spain

Location

MeSH Terms

Conditions

Depressive Disorder, MajorNeurobehavioral Manifestations

Interventions

Cognitive Remediation

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Maria J Portella, Dr

    Fundació Institut de Recerca Hospital de la Santa Creu i Sant Pau

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2025

First Posted

June 11, 2025

Study Start

September 19, 2021

Primary Completion

August 13, 2023

Study Completion

August 13, 2023

Last Updated

June 11, 2025

Record last verified: 2024-09

Locations